TY - JOUR
T1 - Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults
AU - Harvard Aging Brain Study
AU - Gatchel, Jennifer R.
AU - Rabin, Jennifer S.
AU - Buckley, Rachel F.
AU - Locascio, Joseph J.
AU - Quiroz, Yakeel T.
AU - Yang, Hyun Sik
AU - Vannini, Patrizia
AU - Amariglio, Rebecca E.
AU - Rentz, Dorene M.
AU - Properzi, Michael
AU - Donovan, Nancy J.
AU - Blacker, Deborah
AU - Johnson, Keith A.
AU - Sperling, Reisa A.
AU - Marshall, Gad A.
AU - Chhatwal, Jasmeer P.
AU - Dickerson, Bradford
AU - Farrell, Michelle
AU - Velez, Edmarie Guzman
AU - Jacobs, Heidi
AU - Gomez, Cristina Lois
AU - Papp, Kathryn V.
AU - Price, Julie
AU - Pruzin, Jeremy
AU - Schultz, Aaron P.
AU - Sepulcre, Jorge
AU - Skyler-Scott, Irina
AU - Becker, J. Alex
AU - Buckner, Randy
AU - Hedden, Trey
AU - Hanseeuw, Bernard J.
AU - Hujibers, Willem
AU - McGinnis, Scott
AU - Mormino, Elizabeth
AU - Biddle, Kelsey
AU - Fitzpatrick, Colleen
AU - Gonzalez, Christopher
AU - Klein, Hannah
AU - Manning, Lyssa
AU - Muniz, Martha
AU - Samaroo, Aubryn
AU - Sparks, Paige
AU - Torrico-Teave, Heirangi
AU - Fuller, Joshua
AU - Hampton, Olivia
AU - Katz, Samantha
AU - Moody, Kirsten
AU - Mayblyum, Danielle
AU - Barolak, Kelsey
AU - Rubinstein, Zoe
N1 - Publisher Copyright:
© 2019 Gatchel JR et al.
PY - 2019/8/9
Y1 - 2019/8/9
N2 - IMPORTANCE Depressive symptoms are prevalent among older adults and may be early manifestations of Alzheimer disease (AD) before onset of mild cognitive impairment. However, it remains unclear whether worsening depressive symptoms in the presence of AD pathology are associated with cognitive decline in older adults. OBJECTIVE To determine the longitudinal association between depressive symptoms, cognition, and cortical amyloid in community-dwelling older adults. DESIGN, SETTING, AND PARTICIPANTS Participants from the Harvard Aging Brain Study, a cohort study, underwent annual assessments of depression and cognition and baseline cortical amyloid measurement (mean, 4.42 years; range, 2-7 years). Data collection was from September 2010 to August 2017 in a convenience sample of community-dwelling adults (276 participants, all cognitively unimpaired) with at most mild depression at entry. MAIN OUTCOMES AND MEASURES Depression (Geriatric Depression Scale [GDS]), cognition (Preclinical Alzheimer Cognitive Composite [PACC]), and a continuous measure of cortical amyloid (Pittsburgh Compound-B positron emission tomography imaging). Change in GDS and baseline amyloid were examined as interactive predictors of PACC decline in a linear mixed model with backward elimination, adjusting for age, sex, and education. RESULTS Participants were 164 women and 112 men (mean [SD] age, 73.5 [6.0] years). At baseline, the mean (SD) GDS score was 3.0 (2.8) (range, 0-12), the mean (SD) PACC score was -0.004 (0.67) (range, -2.32 to 1.88), and the mean (SD) amyloid positron emission tomography distribution volume ratio was 1.16 (0.20) (range, 0.92-1.94). At last follow-up, the mean (SD) GDS score was 3.9 (2.9) (range, 0-12), and the mean (SD) PACC score was -0.09 (1.27) (range, -5.66 to 1.67). The interaction between cortical amyloid and increasing GDS was associated with declining cognition (β = -0.19; 95% CI, -0.27 to -0.12; P < .001). CONCLUSIONS AND RELEVANCE In this study, cortical amyloid moderated the association between worsening depressive symptoms and declining cognition in older adults. While future work is needed to better understand causal associations, these findings may enhance early detection and prevention of AD clinical symptoms.
AB - IMPORTANCE Depressive symptoms are prevalent among older adults and may be early manifestations of Alzheimer disease (AD) before onset of mild cognitive impairment. However, it remains unclear whether worsening depressive symptoms in the presence of AD pathology are associated with cognitive decline in older adults. OBJECTIVE To determine the longitudinal association between depressive symptoms, cognition, and cortical amyloid in community-dwelling older adults. DESIGN, SETTING, AND PARTICIPANTS Participants from the Harvard Aging Brain Study, a cohort study, underwent annual assessments of depression and cognition and baseline cortical amyloid measurement (mean, 4.42 years; range, 2-7 years). Data collection was from September 2010 to August 2017 in a convenience sample of community-dwelling adults (276 participants, all cognitively unimpaired) with at most mild depression at entry. MAIN OUTCOMES AND MEASURES Depression (Geriatric Depression Scale [GDS]), cognition (Preclinical Alzheimer Cognitive Composite [PACC]), and a continuous measure of cortical amyloid (Pittsburgh Compound-B positron emission tomography imaging). Change in GDS and baseline amyloid were examined as interactive predictors of PACC decline in a linear mixed model with backward elimination, adjusting for age, sex, and education. RESULTS Participants were 164 women and 112 men (mean [SD] age, 73.5 [6.0] years). At baseline, the mean (SD) GDS score was 3.0 (2.8) (range, 0-12), the mean (SD) PACC score was -0.004 (0.67) (range, -2.32 to 1.88), and the mean (SD) amyloid positron emission tomography distribution volume ratio was 1.16 (0.20) (range, 0.92-1.94). At last follow-up, the mean (SD) GDS score was 3.9 (2.9) (range, 0-12), and the mean (SD) PACC score was -0.09 (1.27) (range, -5.66 to 1.67). The interaction between cortical amyloid and increasing GDS was associated with declining cognition (β = -0.19; 95% CI, -0.27 to -0.12; P < .001). CONCLUSIONS AND RELEVANCE In this study, cortical amyloid moderated the association between worsening depressive symptoms and declining cognition in older adults. While future work is needed to better understand causal associations, these findings may enhance early detection and prevention of AD clinical symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85070547385&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2019.8964
DO - 10.1001/jamanetworkopen.2019.8964
M3 - Article
C2 - 31397865
AN - SCOPUS:85070547385
SN - 2574-3805
VL - 2
SP - E198964
JO - JAMA network open
JF - JAMA network open
IS - 8
ER -